Efficacy of Temozolomide in Children with Solid Tumors
Anna Ariano1, Giorgio Attinà1, Silvia Triarico1, Paola Coccia2, Michele Antonio Capozza1, Stefano Mastrangelo1, Palma Maurizi1 and Antonio Ruggiero1
1Pediatric Oncology Unit, Fondazione Policlinico Universitario A .Gemelli IRCCS, Universita’ Cattolica Sacro Cuore, Roma, Italy.
2Pediatric Hemato-oncology Unit, Ospedale Salesi, Azienda Ospedali Riuniti Ancona, Ancona, Italy.
Corresponding Author E-mail : antonio.ruggiero@unicatt.it
Abstract: Temozolomide, an alkylating drug first adopted to treat patients with malignant gliomas, is actually an antineoplastic drug used in various regimens against childhood tumors. Treatment with temozolomide is an effective therapy for different childhood tumor types: brain tumors, neuroblastomas, Ewing's sarcoma, and rhabdomyosarcomas. Temozolomide has been used both as monotherapy and in polychemotherapy in combination with epipodophyllotoxins, camptothecin analogues, platinum compounds, vinca alkaloids and radiotherapy. The present study analyzes the treatment schedules including temozolomide in different cancer pathologies by comparing the results, in order to evaluate the efficacy of each treatment modality.
Keywords: Children; Solid Tumors; Temozolomide Back to TOC